Author:
Kato Chikage,Iizuka-Ohashi Mahiro,Honda Mizuki,Konishi Eiichi,Yokota Isao,Boku Shogen,Mizuta Naruhiko,Morita Midori,Sakaguchi Koichi,Taguchi Tetsuya,Watanabe Motoki,Naoi Yasuto
Funder
Government of Japan Ministry of Education Culture Sports Science and Technology
Reference55 articles.
1. The significance of oncogene amplification in primary breast cancer;Seshadri;Int. J. Cancer,1989
2. HER2-positive breast cancer;Loibl;Lancet,2017
3. Supervised risk predictor of breast cancer based on intrinsic subtypes;Parker;J. Clin. Oncol.,2009
4. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial;Gianni;Lancet Oncol.,2012
5. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial;Baselga;Lancet,2012